On the 9th in the morning, L&C BIO shares are up more than 16%. The rise came after news that the company's China subsidiary has begun full-scale sales in China of its human tissue–based medical devices.
As of 9:09 a.m. on the 9th, L&C BIO is trading on the KOSDAQ market at 78,300 won, up 11,200 won (16.69%) from the previous trading day.
L&C BIO said on the 9th that its China subsidiary L&C China signed a strategic partnership with Shanghai Jiya Life in China for the sales and marketing of "Megaderm Plus." It said full-scale sales in the Chinese market have begun through this arrangement.
Buying appears to have intensified after partner Shanghai Jiya Life became known two years ago as the exclusive sales agent for the No. 1 company in China's local human tissue skin graft market.